• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
WEI Yuanyuan, YANG Fan, TANG Jie, YU Lifang. Advances in the research of anti-tuberculosis drugs[J]. Journal of China Pharmaceutical University, 2020, 51(2): 231-239. DOI: 10.11665/j.issn.1000-5048.20200215
Citation: WEI Yuanyuan, YANG Fan, TANG Jie, YU Lifang. Advances in the research of anti-tuberculosis drugs[J]. Journal of China Pharmaceutical University, 2020, 51(2): 231-239. DOI: 10.11665/j.issn.1000-5048.20200215
shu

Advances in the research of anti-tuberculosis drugs

More Information
    Graphical Abstract
    • Abstract
  • Tuberculosis(TB)treatment is currently falling into a gigantic dilemma-particularly with the increased frequentcy TB resistance, so the development of new anti-tuberculosis drugs is imperative and has received extensive attention. In the past decade, significant progress has been made in this field. Bedaquiline, delamanid and pretomanid have been approved for the clinical use. In addition, many other drugs and combination protocols are undergoing clinical trials. This review focuses on the new chemical entities for TB treatments from multiple perspectives, including the mechanisms of action, in vitro and in vivo pharmacological activities, pharmacokinetic properties and clinical results. Anti-tuberculosis drug research is prospected to provide a reference for drug deve-lopment.
    • FullText(HTML)
    • References (48)
  • [1]
    Geneva: World Health Organization. Global tuberculosisreport 2018[EB/OL].(2018-09-18)[2019-09-11] .https://www.who.int/tb/publications/global_report/en/.
    [2]
    Zumla A,Nahid P,Cole ST.Advances in the development of new tuberculosis drugs and treatment regimens[J].Nat Rev Drug Discov,2013,12(5):388-404.
    [3]
    Falzon D,Jaramillo E,Schunemann HJ,et al.WHO guidelines for the programmatic management of drug-resistant tuberculosis:2011 update[J].Eur Respir J,2011,38(3):516-528.
    [4]
    Brennan PJ.Structure,function,and biogenesis of the cell wall of Mycobacterium tuberculosis[J].Tuberculosis,2003,83(1/2/3):91-97.
    [5]
    Favrot L,Ronning DR.Targeting the mycobacterial envelope for tuberculosis drug development[J].Expert Rev Anti Infect Ther,2012,10(9):1023-1036.
    [6]
    Horsburgh CR,D.M,Barry CE,et al.Treatment of tuberculosis[J].N Engl J Med,2015,373(22):2149-2160.
    [7]
    Matsumoto M,Hashizume H,Tomishige T,et al.OPC-67683,a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice[J].PLoS Med,2006,3(11):2131-2144.
    [8]
    Fujiwara M, Kawasaki M, Hariguchi N, et al. Mechanisms of resistance to delamanid,a drug for Mycobacterium tuberculosis[J].Tuberculosis,2018,108:186-194.
    [9]
    Gler MT,Skripconoka V,Sanchez-Garavito E,et al.Delamanid for multidrug-resistant pulmonary tuberculosis[J].N Engl J Med,2012,366(23):2151-2160.
    [10]
    Liu Y,Matsumoto M,Ishida H,et al.Delamanid:from discovery to its use for pulmonary multidrug-resistant tuberculosis(MDR-TB)[J].Tuberculosis,2018,111:20-30.
    [11]
    Stover CK,Warrener P,Vandevanter DR,et al.A small-moleculenitroimidazopyran drug candidate for the treatment of tuberculosis[J].Nature,2000,405(6789):962-966.
    [12]
    Singh R,Manjunatha U,Helena IMB,et al.PA-824 kills nonreplicating Mycobacterium tuberculosis by intracellular NO release[J].Science,2008,322(5906):1392-1395.
    [13]
    Lenaerts AJ,Veronica G,Marietta KS,et al.Preclinical testing of the nitroimidazopyran PA-824 for activity against Mycobacterium tuberculosis in a series of in vitro and in vivo models[J].Antimicrob Agents Chemother,2005,49(6):2294-2301.
    [14]
    Sandeep T, Nuermberger E, Yoshimatsu T, et al. Bactericidal activity of the nitroimidazopyran PA-824 in a murine model of tuberculosis[J].Antimicrob Agents Chemother,2005,49(6):2289-2293.
    [15]
    Diacon AH, Rodney D, Florian GB, et al. 14-day bactericidal activity of PA-824,bedaquiline,pyrazinamide,and moxifloxacin combinations:a randomised trial[J].Lancet,2012,380(9846):986-993.
    [16]
    Nuermberger E,Tyagi S,Tasneen R,et al.Powerful bactericidal and sterilizing activity of a regimen containing PA-824,moxifloxacin,and pyrazinamide in a murine model of tuberculosis[J].Antimicrob Agents Chemother,2008,52(4):1522-1524.
    [17]
    Nuermberger E,Rosenthal I,Tyagi S,et al.Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis[J].Antimicrob Agents Chemother,2006,50(8):2621-2625.
    [18]
    Tasneen R, Tyagi S, Williams K, et al. Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis[J].Antimicrob Agents Chemother,2008,52(10):3664-3668.
    [19]
    Sacksteder KA,Protopopova M,Barry CE,et al.Discovery and development of SQ109:a new antitubercular drug with a novel mechanism of action[J].Future Microbiol,2012,7(7):823-837.
    [20]
    Chen P.Synergistic interactions of SQ109,a new ethylene diamine,with front-line antitubercular drugs in vitro[J].J Antimicrob Chemoth,2006,58(2):332-337.
    [21]
    Reddy VM, Einck L, Andries K,et al. In vitro interactions between new antitubercular drug candidates SQ109 and TMC207[J].Antimicrob Agents Chemother,2010,54(7):2840-2846.
    [22]
    Reddy VM,Dubuisson T,Einck L,et al.SQ109 and PNU-100480 interact to kill Mycobacterium tuberculosis in vitro[J].J Antimicrob Chemoth,2012,67(5):1163-1166.
    [23]
    Piton J,Vocat A,Lupien A,et al.Structure-based drug design and characterization of sulfonyl-piperazine benzothiazinone inhibitors of DprE1 from Mycobacterium tuberculosis[J].Antimicrob Agents Chemother,2018,62(10):e00681-18.
    [24]
    Brecik M,Centárová I,Mukherjee R,et al.DprE1 is a vulnerable tuberculosis drug target due to its cell wall localization[J].ACS Chem Biol,2015,10(7):1631-1636.
    [25]
    Makarov V,Manina G,Mikusova K,et al.Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis[J].Science,2009,324(5928):801-804.
    [26]
    Lechartier B,Hartkoorn RC,Cole ST.In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis[J].Antimicrob Agents Chemother,2012,56(11):5790-5793.
    [27]
    Makarov V,Lechartier B,Zhang M,et al.Towards a new combination therapy for tuberculosis with next generation benzothiazinones[J].Embo Mol Med,2014,6(3):372-383.
    [28]
    Makarov V,Neres J,Hartkoorn RC,et al.The 8-pyrrole-benzothiazinones are noncovalent inhibitors of DprE1 from Mycobacterium tuberculosis[J].Antimicrob Agents Chemother,2015,59(8):4446-4452.
    [29]
    Lechartier B,Cole ST.Mode of action of clofazimine and combination therapy with benzothiazinones against Mycobacterium tuberculosis[J].Antimicrob Agents Chemother,2015,59(8):4457-4463.
    [30]
    Lupien A,Vocat A,Foo CS,et al.Optimized background regimen for treatment of active tuberculosis with the next-generation benzothiazinone Macozinone(PBTZ169)[J].Antimicrob Agents Chemother,2018,62(11):e00840-18.
    [31]
    Working Group on New TB Drugs[EB/OL].[2019-09-11] .https://www.newtbdrugs.org/pipeline/clinical.
    [32]
    Chatterji M,Shandil R,Manjunatha MR,et al.1,4-azaindole,a potential drug candidate for treatment of tuberculosis[J].Antimicrob Agents Chemother,2014,58(9):5325-5331.
    [33]
    Lamprecht DA,Finin PM,Rahman MA,et al.Turning the respi-ratory flexibility of Mycobacterium tuberculosis against itself[J].Nat Commun,2016,7(1):12393.
    [34]
    Kalia NP,Hasenoehrl EJ,Ab Rahman NB,et al.Exploiting the synthetic lethality between terminal respiratory oxidases to kill Mycobacterium tuberculosis and clear host infection[J].PNAS,2017,114(28):7426-7431.
    [35]
    Guillemont J,Meyer C,Poncelet A,et al.Diarylquinolines,synthesis pathways and quantitative structure-activity relationship studies leading to the discovery of TMC207[J].Future Med Chem,2011,3(11):1345-1360.
    [36]
    Ahmad N,Ahuja SD,Akkerman OW,et al.Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis:an individual patient data meta-analysis[J].Lancet,2018,392(10150):821-834.
    [37]
    Abrahams KA,Cox JA,Spivey VL,et al.Identification of novel imidazo[1,2-a]pyridine inhibitors targeting M.tuberculosis QcrB[J].PLoS One,2012,7(12):e52951.
    [38]
    Pethe K,Bifani P,Jang J,et al.Discovery of Q203,a potent clinical candidate for the treatment of tuberculosis[J].Nat Med,2013,19(9):1157-1160.
    [39]
    Barbachyn MR,Hutchinson DK,Brickner SJ,et al.Identification of a novel oxazolidinone(U-100480)with potent antimycobacterial activity[J].J Med Chem,1996,39(3):680-685.
    [40]
    Williams KN,Stover CK,Zhu T,et al.Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model[J].Antimicrob Agents Chemother,2009,53(4):1314-1319.
    [41]
    Williams KN,Brickner SJ,Stover CK,et al.Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis[J].Am J Resp Crit Care,2009,180(4):371-376.
    [42]
    Wallis RS,Jakubiec WM,Kumar V,et al.Pharmacokinetics and whole-blood bactericidal activity against Mycobacterium tuberculosis of single doses of PNU-100480 in healthy volunteers[J].J Infect Dis,2010,202(5):745-751.
    [43]
    Wallis RS,Jakubiec W,Kumar V,et al.Biomarker-assisted dose selection for safety and efficacy in early development of PNU-100480 for tuberculosis[J].Antimicrob Agents Chemother,2011,55(2):567-574.
    [44]
    Li X,Hernandez V,Rock FL,et al.Discovery of a potent and specific M.tuberculosis leucyl-tRNA synthetase inhibitor:(S)-3-(aminomethyl)-4-chloro-7-(2-hydroxyethoxy)benzo[c][1,2] oxaborol-1(3H)-ol(GSK656)[J].J Med Chem,2017,60(19):8011-8026.
    [45]
    Tenero D,Derimanov G,Carlton A,et al.First-time-in-human study and prediction of early bactericidal activity for GSK3036656,a potent leucyl-tRNA synthetase inhibitor for tuberculosis treatment[J].Antimicrob Agents Chemother,2019,63(8):e00240-19.
    [46]
    Ralph AP,Kenangalem E,Waramori G,et al.High morbidity during treatment and residual pulmonary disability in pulmonary tuberculosis:under-recognised phenomena[J].PLoS One,2013,8(11):e80302.
    [47]
    Willcox PA,Ferguson AD.Chronic obstructive airways disease following treated pulmonary tuberculosis[J].Resp Med,1989,83(3):195-198.
    [48]
    Wallis RS,Maeurer M,Mwaba P,et al.Tuberculosis—advances in development of new drugs,treatment regimens,host-directed therapies,and biomarkers[J].Lancet Infect Dis,2016,16(4):e34-e46.
    • Related Articles

  • Related Articles

    [1]LI Linzhen, WEI Xi, LIU Lu, LI Yongjun, LIANG Jingyu. Chemical constituents from the stems of Clerodendrum trichotomum Thunb.[J]. Journal of China Pharmaceutical University, 2019, 50(5): 544-548. DOI: 10.11665/j.issn.1000-5048.20190506
    [2]LIN Qinghua, XU Jian, FENG Feng. Chemical constituents from the stems of Picrasma quassioides Bennet[J]. Journal of China Pharmaceutical University, 2017, 48(6): 675-679. DOI: 10.11665/j.issn.1000-5048.20170607
    [3]XU Yunhui, JIANG Xueyang, XU Jian, JIANG Renwang, ZHANG Jie, XIE Zijian, FENG Feng. Chemical constituents from Callicarpa kwangtungensis Chun[J]. Journal of China Pharmaceutical University, 2016, 47(3): 299-302. DOI: 10.11665/j.issn.1000-5048.20160309
    [4]YU Shule, MA Lin, WU Zhengfeng, ZHAO Shouxun, WANG Lei, YE Wencai, ZHANG Jian, YIN Zhiqi. Non-C21 steroids from the Rhizome of Cynanchum stauntonii[J]. Journal of China Pharmaceutical University, 2015, 46(4): 426-430. DOI: 10.11665/j.issn.1000-5048.20150407
    [5]MA Lin, ZHANG Rongfei, YU Shule, WU Zhengfeng, ZHAO Shouxun, Wang Lei, YE Wencai, ZHANG Jian, YIN Zhiqi. Chemical constituents of Fructus Gleditsiae Abnormalis[J]. Journal of China Pharmaceutical University, 2015, 46(2): 188-193. DOI: 10.11665/j.issn.1000-5048.20150209
    [6]LI Linzhen, WANG Menghua, SUN Jianbo, LIANG Jingyu. Chemical constituents from Aletris spicata[J]. Journal of China Pharmaceutical University, 2014, 45(2): 175-177. DOI: 10.11665/j.issn.1000-5048.20140208
    [7]CHANG Bo, XIAO Linjing, ZHANG Jian, ZHAO Shouxun, YE Wencai, YIN Zhiqi. Chemical constituents from Abies ernestii var.salouenensis[J]. Journal of China Pharmaceutical University, 2014, 45(1): 43-47. DOI: 10.11665/j.issn.1000-5048.20140107
    [8]LI Jiu-hui, CHEN Guang-ying, HAN Chang-ri, MO Zheng-rong, SONG Xiao-ping. Chemical constituents from the stems of Vatica mangachpoi Blanco[J]. Journal of China Pharmaceutical University, 2012, 43(1): 25-27.
    [9]SUN Jing, YIN Zhi-qi, ZHANG Qing-wen, YE Wen-cai, WANG Yi-ta, ZHAO Shou-xun. Chemical constituents from ethyl acetate extract of Ganoderma lucidum[J]. Journal of China Pharmaceutical University, 2011, 42(3): 220-222.
    [10]Chemical constituents from Senecio nemorensis.[J]. Journal of China Pharmaceutical University, 2010, 41(1): 26-28.

Catalog

    Get Citation
    PDF
    XML
    Article views (613) PDF downloads (1150) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：278745

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return